Enfusion Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Revenue	174.54	150.35	111.7	79.57	59.03
Revenue Growth (YoY)	16.09%	34.60%	40.39%	34.79%	-
Cost of Revenue	57.64	47.1	31.85	21.36	16.96
Gross Profit	116.89	103.25	79.86	58.21	42.07
Selling, General & Admin	85.05	98.05	202.34	45.82	24.05
Research & Development	19.89	17.16	153.4	6.32	4.15
Operating Expenses	104.95	115.21	355.74	52.13	28.2
Operating Income	11.95	-11.96	-275.88	6.07	13.87
Interest Expense / Income	-1.64	-0.41	4.59	1.66	0.72
Other Expense / Income	5.33	-4.97	-122.74	-0.08	0
Pretax Income	8.26	-6.58	-157.74	4.49	13.14
Income Tax	2.23	1.07	0.58	0.43	0.49
Net Income	6.03	-7.65	-158.32	4.06	12.66
Net Income Growth	-	-	-	-67.91%	-
Shares Outstanding (Basic)	88	85	83	113	-
Shares Outstanding (Diluted)	129	85	83	-	-
Shares Change	51.57%	2.83%	-26.54%	-	-
EPS (Basic)	0.07	-0.10	-2.26	-	-
EPS (Diluted)	0.07	-0.10	-2.26	-	-
Free Cash Flow	15.96	6.23	-8.33	-3.4	7.88
Free Cash Flow Per Share	0.18	0.07	-0.10	-0.03	-
Gross Margin	66.97%	68.67%	71.49%	73.16%	71.27%
Operating Margin	6.85%	-7.96%	-246.99%	7.63%	23.50%
Profit Margin	3.45%	-5.09%	-141.73%	5.10%	21.44%
Free Cash Flow Margin	9.15%	4.14%	-7.46%	-4.28%	13.34%
Effective Tax Rate	27.02%	-	-	9.64%	3.70%
EBITDA	23.48	4.7	-149.17	8.45	15.02
EBITDA Margin	13.46%	3.13%	-133.54%	10.62%	25.45%
Depreciation & Amortization	16.87	11.7	3.98	2.29	1.16
EBIT	6.62	-6.99	-153.14	6.16	13.87
EBIT Margin	3.79%	-4.65%	-137.10%	7.74%	23.49%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).